Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis

This study tests whether a combination of two medications — iguratimod and tofacitinib — works better than standard treatment in patients with rheumatoid arthritis (RA) who have not responded well to conventional disease-modifying drugs and are being considered for a more intensive treatment. **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with rheumatoid arthritis - Your RA is actively inflamed with swollen and tender joints and elevated inflammation markers in blood tests - You have been on standard RA medications for at least 3 months without adequate improvement - You can give yourself injections or have someone available to give them to you **You may NOT be eligible if...** - You have previously been treated with biologic RA drugs - You are allergic to the medications used in this study - You have recently stopped certain strong immune-suppressing drugs (less than 4 weeks ago) - You have recently received or plan to receive a live vaccine during the study Talk to your doctor to see if this trial is right for you.